Table 1.

Patients, Markers, and DTC Detection Methods Used at each Site

	JHH	USC	UW	FHCRC
LOCALIZED BM PATIENTS	106 Localized BM	43 Localized BM	18 Localized BM	41 Localized BM
LOCALIZED COHORT OVERLAP	16 patients overlap between JHH and USC		2 patients overlap between UW and FHCRC
ADDITIONAL PATIENT SAMPLES	16 Control BM 5 Metastatic BM 37 Metastatic PB	5 Localized PB	None	None
DTC DETECTION METHOD	AdnaTest	HD-SCA	VERSA	RareCyte
TEST CATEGORY	mRNA	IF	mRNA	IF
MARKERS $\mathbf{\text{Nuclear}}$ WBC $\mathbf{\text{Prostate-Specific}}$ $\mathbf{\text{ProstateRelated}}$ $\mathbf{\text{Non-Specific}}$ $\mathbf{\text{Unknown Prostate}}$ $\mathbf{\text{Specificity}}$ $\mathbf{\text{Epithelial}}$	$\mathbf{\text{PSA}}$ $\mathbf{\text{HOXB}}\mathbf{13}$ $\mathbf{\text{AR}}$ $\mathbf{\text{NKX}}\mathbf{3.1}$ $\mathbf{\text{EpCAM}}$	$\mathbf{\text{DAPI}}$ CD45 $\mathbf{\text{AR}}$ $\mathbf{\text{CK}}$	$\mathbf{\text{PSA}}$ $\mathbf{\text{HOXB}}\mathbf{13}$ $\mathbf{\text{AR}}$ $\mathbf{\text{PAP}}$ $\mathbf{\text{NKX}}\mathbf{3.1}$ $\mathbf{\text{TMPRSS}}2$ $\mathbf{\text{PSMA}}$ $\mathbf{\text{EpCAM}}$ $\mathbf{\text{KRT}}\mathbf{8}$	$\mathbf{\text{SYTOX}}$ CD45 $\mathbf{\text{AR}}$ $\mathbf{4}\mathbf{P}\mathbf{=}\mathbf{\left(}\mathbf{\text{PSA}}\mathbf{+}\mathbf{\text{PAP}}\mathbf{,}\mathbf{\text{PSCA}}\mathbf{,}\mathbf{\text{PSMA}}\mathbf{\right)}$ $\mathbf{\text{CK}}$ $\mathbf{\text{EpCAM}}$
LOCALIZED PATIENTS WITH DTCs	1 patient PSA+	Non-specific assay 1 patient with AR+ cells	1 patient PSMA+	Non-specific assay 1 patient with DTCs = (4P+/AR+/CK+/EpCAM+/CD45−)